Laddar populära aktier...
I samband med att aXichem AB (publ) (”aXichem” eller ”Bolaget”) genomför sin företrädesemission har Analyst Group publicerat en analysartike...
Redeye ceases its coverage of aXichem due to the end of the contractual period.
Redeye comments on aXichem’s Q3 2022 report. The report did not include any surprises where sales came in at SEK0.
Redeye decreases its fair value range for aXichem after reviewing the case and making significant changes to our financial estimates to appl...
Redeye endorses aXichem’s new patent for phenylcapsaicin for use in the treatment of idiopathic pulmonary fibrosis.
Redeye endorses aXichem’s new order of USD280,000 from Iovate.
Redeye endorses that aXichem has obtained a patent regarding phenylcapsaicin in treating leaky gut.
Redeye comments on aXichem’s Q2’22 report. We are encouraged to see sales for H1 2022 reaching SEK 1.
Redeye is positive about the clinical study results showing that a low dose of phenylcapsaicin likely has a positive effect on humans with l...
Redeye endorses aXichem signing a supply and research agreement worth around USD 5m with the Canadian nutrition company, Iovate Health Scien...
Redeye provides its comments on aXichem’s Q1’22 report.
Redeye is encouraged to learn that aXichem will be collaborating with LIFEPro Nutrition and Indiex Sport Nutrition in a study with elite ath...
Redeye is encouraged to learn that aXichem has been granted a new patent in Brazil for phenylcapsaicin as an ingredient in bird feed, partic...
Redeye provides a short comment on yesterday’s news regarding aXichem’s intention to take up a convertible loan of SEK 20m to execute on its...
Redeye endorses aXichem applying for Feed Additive in the EU and views this as an important milestone for the company.
Redeye endorses aXichem receiving yet another aXivite order from its Polish distributor BART.
Redeye endorses aXichem filing a patent application for phenylcapsaicin as a bio-enhancer for substrates of certain Cytochrome P450 Isoforms...
Redeye comments on aXichem’s Q4’21 report. The last quarter of 2021 included some interesting events, and the company is on the right path t...
Redeye endorses aXichem signing a business collaboration agreement with GCV Life to commercialize aXivite in the fast-growing Indian market ...
Redeye returns with an update of aXichem following the Q2’21 report and has reviewed the case in detail.
Redeye comments on aXichem’s Q2’21 report. The report did not include any major surprises, but we believe that the company has an interestin...
Redeye is positive about Tuesday’s press release from aXichem, where it announced it has fully verified its production process.
